scholarly journals Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer

BJUI Compass ◽  
2021 ◽  
Author(s):  
Angelyn Anton ◽  
Sruti Pillai ◽  
Marie Christine Semira ◽  
Shirley Wong ◽  
Julia Shapiro ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Systemic Therapy ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Castration Resistant

The effect of treatment sequence on overall survival for men with metastatic castration-resistant prostate cancer: A multicenter retrospective study.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 238-238
Author(s):  
Shingo Hatakeyama ◽  
Kazutaka Okita ◽  
Hayato Yamamoto ◽  
Takahiro Yoneyama ◽  
Yasuhiro Hashimoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Real World ◽  
Cox Regression ◽  
Sequential Therapy ◽  
Treatment Sequence ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Castration Resistant ◽  
Significant Difference

238 Background: We aimed to evaluate the treatment sequence for patients with metastatic castration-resistant prostate cancer (mCRPC) in real-world practice and compare overall survival in each sequential therapy. Methods: We retrospectively evaluated 146 patients with mCRPC who were initially treated with androgen deprivation therapy as metastatic hormone-naïve prostate cancer in 14 hospitals between January 2010 and March 2019. The agents for the sequential therapy included new androgen receptor-targeted agents (ART: abiraterone acetate or enzalutamide), docetaxel, and/or cabazitaxel. We evaluated the treatment sequence for mCRPC and the effect of sequence patterns on overall survival. Results: The median age was 71 years. A total of 35 patients received ART-ART, 33 received ART-docetaxel, 68 received docetaxel-ART, and 10 received docetaxel-cabazitaxel sequences. The most prescribed treatment sequence was docetaxel-ART (47%), followed by ART-ART (24%). Overall survival calculated from the initial diagnosis reached 83, 57, 79, 37 months in the ART-ART, ART-docetaxel, docetaxel-ART, and docetaxel-cabazitaxel, respectively. Multivariate Cox regression analyses showed no significant difference in overall survival between the first-line ART (n = 68) and first-line docetaxel (n = 78) therapies (hazard ratio: HR 0.84, P = 0.530), between the ART-ART (n = 35) and docetaxel-mixed (n = 111) sequences (HR 0.82, P = 0.650), and between the first-line abiraterone (n = 32) and first-line enzalutamide (n = 36) sequences (HR 1.58, P = 0.384). Conclusions: The most prescribed treatment sequence was docetaxel followed by ART. No significant difference was observed in overall survival among the treatment sequences in real-world practice.

scholarly journals Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

2020 ◽  
Vol 15 (3) ◽  
pp. 301-315 ◽  
Author(s):  
Simon Chowdhury ◽  
Anders Bjartell ◽  
Nicolaas Lumen ◽  
Pablo Maroto ◽  
Thomas Paiss ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Registry ◽  
Real World ◽  
Line Treatment ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Castration Resistant ◽  
First Line Treatment

Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

2021 ◽  
pp. ejhpharm-2021-002798
Author(s):  
Macarena García Trevijano Cabetas ◽  
Miguel Escario-Gómez ◽  
Luis González-Del Valle ◽  
Carmen Sobrino Jiménez ◽  
Cristina Bilbao Gomez-Martino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Real World ◽  
Line Treatment ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Castration Resistant ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document